J Clin Oncol: The efficacy of radiotherapy (RT) and androgen deprivation therapy (ADT) with or without docetaxel in the treatment of non-metastatic, adverse-risk prostate cancer: a prospective randomized study

After observing the overall survival (OS) benefit in two randomized controlled trials (RCT), the docetaxel (Docetaxel) for the first time by the US Food and Drug Administration Bureau ( the FDA ) approved for use in men with metastatic (M1) to Potentially resistant prostate cancer (PC) patients

After observing the overall survival (OS) benefit in two randomized controlled trials (RCT), the docetaxel (Docetaxel) for the first time by the US Food and Drug Administration Bureau ( the FDA ) approved for use in men with metastatic (M1) to Potentially resistant prostate cancer (PC) patients

The study (NCT00116142) is a multi-center randomized study initiated by the investigator

The study (NCT00116142) is a multi-center randomized study initiated by the investigator

The median follow-up time was 10.

Efficacy evaluation

For patients with PSA<4 ng/mL vs.

For patients with PSA<4 ng/mL vs.

For patients with PSA>20 ng/mL vs.

PSA layered evaluation OS

The proportion of discontinued treatment in the docetaxel group and the ADT+RT group were 4.

In summary, for non-metastatic, adverse-risk prostate cancer patients, adding docetaxel to radiotherapy (RT) and androgen deprivation therapy (ADT) does not prolong OS

Original source:

D'Amico AV, Xie W, McMahon E, et al.

D'Amico AV, Xie W, McMahon E, et al.
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
J Clin Oncol.
2021 Jul 1:JCO2100596.
doi : 10.
1200/JCO.
21.
00596.
Epub ahead of print.
PMID: 34197181.


Leave a message here